# Alatawi et al.: Microbiota and anti-TNF-α response in IBD patients

opportunistic pathogenic microbiota, and a lack of SCFA-producing bacteria. A decreased abundance of SCFA-producing bacteria, including Anaerostipes, Coprococcus, Lachnospira, Roseburia, and Ruminococcus, was detected in unresponsive patients. Particular fecal microbiota may be used as biomarkers to predict clinical response to anti-TNF-α medication. The potential biomarkers for primary non-response patients identified were Klebsiella, Eubacteriaceae, RF32, B. animalis, and Muribaculaceae.

# REFERENCES

1. Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 2016;7(1):1-14. https://doi.org/10.1038/ncomms11624
2. Madan JC, Salari RC, Saxena D, Davidson L, O’Toole GA, Moore JH, et al. Gut microbial colonisation in premature neonates predicts neonatal sepsis. Arch Dis Child Fetal Neonatal Ed 2012;97(6):F456-62. https://doi.org/10.1136/fetalneonatal-2011-301373
3. Zhang M, Sun K, Wu Y, Yang Y, Tso P, Wu Z. Interactions between intestinal microbiota and host immune response in inflammatory bowel disease. Front Immunol 2017;8:942. https://doi.org/10.3389/fimmu.2017.00942
4. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140(6):1785-94.e4. https://doi.org/10.1053/j.gastro.2011.01.055
5. Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, et al. Evolution of mammals and their gut microbes. Science 2008;320(5883):1647. https://doi.org/10.1126/science.1155725
6. Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci 2020;21(3):270-83. https://doi.org/10.17305/bjbms.2020.5016
7. Sansonetti PJ, Medzhitov R. Learning tolerance while fighting ignorance. Cell. 2009;138(3):416-20. https://doi.org/10.1016/j.cell.2009.07.024
8. Andoh A. Physiological role of gut microbiota for maintaining human health. Digestion 2016;93(3):176-81. https://doi.org/10.1159/000444066
9. Pomare EW, Branch WJ, Cummings JH. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 1985;75(5):1448-54. https://doi.org/10.1172/jci111847
10. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122(1):44-54. https://doi.org/10.1053/gast.2002.30294
11. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: A large single centre experience. J Crohns Colitis 2012;6(2):143-53. https://doi.org/10.1016/j.crohns.2011.07.011
12. Alatawi H, Mosli M, Saadah O, Dulai P, Al-Hindi R, Bahieldin A, et al. Primary non-response in inflammatory bowel disease, definition, potential causes, therapeutic drug monitoring and microbiota-a review. Appl Ecol environ Res 2020;18(4):5505-25. https://doi.org/10.15666/aeer/1804_55055525
13. Fadrosh DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, et al. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome 2014;2(1):6. https://doi.org/10.1186/2049-2618-2-6
14. Magoč T, Salzberg SL. FLASH: Fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011;27:2957-63. https://doi.org/10.1093/bioinformatics/btr507
15. Edgar RC, Flyvbjerg H. Error filtering, pair assembly and error correction for next-generation sequencing reads. Bioinformatics 2015;31:3476-82. https://doi.org/10.1093/bioinformatics/btv401
16. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006;72(7):5069-72. https://doi.org/10.1128/aem.03006-05
17. Ding N, McDonald J, Perdones-Montero A, Rees DN, Adegbola S, Misra R, et al. Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn’s disease. J Crohns Colitis 2020;14(8):1090-102. https://doi.org/10.1093/ecco-jcc/jjaa039
18. Bazin T, Hooks KB, Barnetche T, Truchetet ME, Enaud R, Richez C, et al. Microbiota composition may predict anti-TNF alpha response in spondyloarthritis patients: An exploratory study. Sci Rep 2018;8(1):5446. https://doi.org/10.1038/s41598-018-23571-4
19. Wang Y, Gao X, Ghozlane A, Hu H, Li X, Xiao Y, et al. Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy. J Crohns Colitis 2018;12:337-46. https://doi.org/10.1093/ecco-jcc/jjx153
20. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015;21(8):895-905.
21. Shin NR, Whon TW, Bae JW. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 2015;33(9):496-503. https://doi.org/10.1016/j.tibtech.2015.06.011
22. Santos Rocha C, Gomes-Santos AC, Garcias Moreira T, de Azevedo M, Luerce TD, Mariadassou M, et al. Local and systemic immune mechanisms underlying the anti-colitis effects of the dairy bacterium lactobacillus delbrueckii. PLoS One. 2014;9(1):e85923. https://doi.org/10.1371/journal.pone.0085923
23. Mottawea W, Chiang CK, Mühlbauer M, Starr AE, Butcher J, Abujamel T, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun 2016;7(1):13419. https://doi.org/10.1038/ncomms13419
24. Golińska E, Tomusiak A, Gosiewski T, Więcek G, Machul A, Mikołajczyk D, et al. Virulence factors of Enterococcus strains isolated from patients with inflammatory bowel disease. World J Gastroenterol 2013;19(23):3562-72. https://doi.org/10.3748/wjg.v19.i23.3562
25. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe 2007;2(2):119-29. https://doi.org/10.1016/j.chom.2007.06.010
26. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002;17(8):849-53. https://doi.org/10.1046/j.1440-1746.2002.02834.x
27. Rhee K-J, Wu S, Wu X, Huso DL, Karim B, Franco AA, et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 2009;77(4):1708-18. https://doi.org/10.1128/iai.00814-08
28. Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion 2016;93(1):59-65. https://doi.org/10.1159/000441768
29. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al.